Causes of death among people who used illicit opioids in England, 2001-18: a matched cohort study.


Journal

The Lancet. Public health
ISSN: 2468-2667
Titre abrégé: Lancet Public Health
Pays: England
ID NLM: 101699003

Informations de publication

Date de publication:
02 2022
Historique:
received: 09 08 2021
revised: 27 10 2021
accepted: 01 11 2021
pubmed: 16 12 2021
medline: 17 2 2022
entrez: 15 12 2021
Statut: ppublish

Résumé

In many countries, the average age of people who use illicit opioids, such as heroin, is increasing. This has been suggested to be a reason for increasing numbers of opioid-related deaths seen in surveillance data. We aimed to describe causes of death among people who use illicit opioids in England, how causes of death have changed over time, and how they change with age. In this matched cohort study, we studied patients in the Clinical Practice Research Datalink with recorded illicit opioid use (defined as aged 18-64 years, with prescriptions or clinical observations that indicate use of illicit opioids) in England between Jan 1, 2001, and Oct 30, 2018. We also included a comparison group, matched (1:3) for age, sex, and general practice with no records of illicit opioid use before cohort entry. Dates and causes of death were obtained from the UK Office for National Statistics. The cohort exit date was the earliest of date of death or Oct 30, 2018. We described rates of death and calculated cause-specific standardised mortality ratios. We used Poisson regression to estimate associations between age, calendar year, and cause-specific death. We collected data for 106 789 participants with a history of illicit opioid use, with a median follow-up of 8·7 years (IQR 4·3-13·5), and 320 367 matched controls with a median follow-up of 9·5 years (5·0-14·4). 13 209 (12·4%) of 106 789 participants in the exposed cohort had died, with a standardised mortality ratio of 7·72 (95% CI 7·47-7·97). The most common causes of death were drug poisoning (4375 [33·1%] of 13 209), liver disease (1272 [9·6%]), chronic obstructive pulmonary disease (COPD; 681 [5·2%]), and suicide (645 [4·9%]). Participants with a history of illicit opioid use had higher mortality rates than the comparison group for all causes of death analysed, with highest standardised mortality ratios being seen for viral hepatitis (103·5 [95% CI 61·7-242·6]), HIV (16·7 [9·5-34·9]), and COPD (14·8 [12·6-17·6]). In the exposed cohort, at age 20 years, the rate of fatal drug poisonings was 271 (95% CI 230-313) per 100 000 person-years, accounting for 59·9% of deaths at this age, whereas the mortality rate due to non-communicable diseases was 31 (16-45) per 100 000 person-years, accounting for 6·8% of deaths at this age. Deaths due to non-communicable diseases increased more rapidly with age (1155 [95% CI 880-1431] deaths per 100 000 person-years at age 50 years; accounting for 52·0% of deaths at this age) than did deaths due to drug poisoning (507 (95% CI 452-562) per 100 000 person-years at age 50 years; accounting for 22·8% of deaths at this age). Mirroring national surveillance data, the rate of fatal drug poisonings in the exposed cohort increased from 345 (95% CI 299-391) deaths per 100 000 person-years in 2010-12 to 534 (468-600) per 100 000 person-years in 2016-18; an increase of 55%, a trend that was not explained by ageing of participants. People who use illicit opioids have excess risk of death across all major causes of death we analysed. Our findings suggest that population ageing is unlikely to explain the increasing number of fatal drug poisonings seen in surveillance data, but is associated with many more deaths due to non-communicable diseases. National Institute for Health Research.

Sections du résumé

BACKGROUND
In many countries, the average age of people who use illicit opioids, such as heroin, is increasing. This has been suggested to be a reason for increasing numbers of opioid-related deaths seen in surveillance data. We aimed to describe causes of death among people who use illicit opioids in England, how causes of death have changed over time, and how they change with age.
METHODS
In this matched cohort study, we studied patients in the Clinical Practice Research Datalink with recorded illicit opioid use (defined as aged 18-64 years, with prescriptions or clinical observations that indicate use of illicit opioids) in England between Jan 1, 2001, and Oct 30, 2018. We also included a comparison group, matched (1:3) for age, sex, and general practice with no records of illicit opioid use before cohort entry. Dates and causes of death were obtained from the UK Office for National Statistics. The cohort exit date was the earliest of date of death or Oct 30, 2018. We described rates of death and calculated cause-specific standardised mortality ratios. We used Poisson regression to estimate associations between age, calendar year, and cause-specific death.
FINDINGS
We collected data for 106 789 participants with a history of illicit opioid use, with a median follow-up of 8·7 years (IQR 4·3-13·5), and 320 367 matched controls with a median follow-up of 9·5 years (5·0-14·4). 13 209 (12·4%) of 106 789 participants in the exposed cohort had died, with a standardised mortality ratio of 7·72 (95% CI 7·47-7·97). The most common causes of death were drug poisoning (4375 [33·1%] of 13 209), liver disease (1272 [9·6%]), chronic obstructive pulmonary disease (COPD; 681 [5·2%]), and suicide (645 [4·9%]). Participants with a history of illicit opioid use had higher mortality rates than the comparison group for all causes of death analysed, with highest standardised mortality ratios being seen for viral hepatitis (103·5 [95% CI 61·7-242·6]), HIV (16·7 [9·5-34·9]), and COPD (14·8 [12·6-17·6]). In the exposed cohort, at age 20 years, the rate of fatal drug poisonings was 271 (95% CI 230-313) per 100 000 person-years, accounting for 59·9% of deaths at this age, whereas the mortality rate due to non-communicable diseases was 31 (16-45) per 100 000 person-years, accounting for 6·8% of deaths at this age. Deaths due to non-communicable diseases increased more rapidly with age (1155 [95% CI 880-1431] deaths per 100 000 person-years at age 50 years; accounting for 52·0% of deaths at this age) than did deaths due to drug poisoning (507 (95% CI 452-562) per 100 000 person-years at age 50 years; accounting for 22·8% of deaths at this age). Mirroring national surveillance data, the rate of fatal drug poisonings in the exposed cohort increased from 345 (95% CI 299-391) deaths per 100 000 person-years in 2010-12 to 534 (468-600) per 100 000 person-years in 2016-18; an increase of 55%, a trend that was not explained by ageing of participants.
INTERPRETATION
People who use illicit opioids have excess risk of death across all major causes of death we analysed. Our findings suggest that population ageing is unlikely to explain the increasing number of fatal drug poisonings seen in surveillance data, but is associated with many more deaths due to non-communicable diseases.
FUNDING
National Institute for Health Research.

Identifiants

pubmed: 34906332
pii: S2468-2667(21)00254-1
doi: 10.1016/S2468-2667(21)00254-1
pmc: PMC8810398
pii:
doi:

Substances chimiques

Illicit Drugs 0
Narcotics 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e126-e135

Subventions

Organisme : Medical Research Council
ID : MR/N00616X/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4·0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests MH reports honoraria for speaking at meetings from Gilead, AbbVie, and MSD. AH is co-chair of the Faculty of Public Health Drugs Special Interest Group and a member of the senior research team for the Loop; and he was previously associate director of International Doctors for Healthier Drug Policy. PP was a co-applicant on a grant awarded to the University of Bristol by Bristol and Weston Hospitals Charity focusing on suicide prevention for people presenting to hospital with self-harm and harmful substance use. All other authors declare no competing interests.

Références

Drug Alcohol Depend. 2015 Jan 1;146:17-23
pubmed: 25454405
MMWR Morb Mortal Wkly Rep. 2017 Nov 03;66(43):1197-1202
pubmed: 29095804
Wellcome Open Res. 2020 Dec 3;5:282
pubmed: 33659712
Eur J Epidemiol. 2019 Jan;34(1):91-99
pubmed: 30219957
Drug Alcohol Depend. 2013 Jul 1;131(1-2):23-35
pubmed: 23490450
Bull World Health Organ. 2013 Feb 1;91(2):102-23
pubmed: 23554523
Drug Alcohol Depend. 2019 Nov 1;204:107525
pubmed: 31581023
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Stat Med. 2019 Sep 30;38(22):4390-4403
pubmed: 31313337
JAMA Psychiatry. 2020 May 1;77(5):493-502
pubmed: 31876906
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):443-51
pubmed: 15898131
Curr Opin Psychiatry. 2021 Jul 1;34(4):344-350
pubmed: 33965972
Lancet Public Health. 2020 Jan;5(1):e33-e41
pubmed: 31813773
Addiction. 1997 Apr;92(4):419-27
pubmed: 9177063
J Psychiatr Res. 2020 Nov;130:435-440
pubmed: 32905957
Lancet Gastroenterol Hepatol. 2018 Nov;3(11):754-767
pubmed: 30245064
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
Addiction. 2011 Jan;106(1):32-51
pubmed: 21054613
Clin Rev Allergy Immunol. 2014 Feb;46(1):82-100
pubmed: 23760760
J Chronic Dis. 1985;38(10):811-30
pubmed: 4044767
Health Soc Care Community. 2008 Mar;16(2):147-54
pubmed: 18290980
Addiction. 2014 Jan;109(1):90-9
pubmed: 23961881
Addiction. 2002 Jan;97(1):39-47
pubmed: 11895269
Int J Epidemiol. 2019 Dec 1;48(6):1740-1740g
pubmed: 30859197

Auteurs

Dan Lewer (D)

Department of Epidemiology and Public Health, University College London, London, UK. Electronic address: d.lewer@ucl.ac.uk.

Thomas D Brothers (TD)

Department of Epidemiology and Public Health, University College London, London, UK; Department of Medicine, Dalhousie University, Halifax, NS, Canada.

Naomi Van Hest (N)

Department of Epidemiology and Public Health, University College London, London, UK.

Matthew Hickman (M)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Adam Holland (A)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; Department of Public Health, Environments and Society, London School of Hygiene & Tropical Medicine, London, UK.

Prianka Padmanathan (P)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Paola Zaninotto (P)

Department of Epidemiology and Public Health, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH